Abrocitinib Summary of Clinical Safety (Atopic Dermatitis)
Proportion and Incidence Rates for Treatment-Emergent Hypoglycemia (All Causalities) - Long-Term Dose-Controlled Pool 2024

		Abrocitinib 100mg QD (N=1053)	Abrocitinib 200mg QD (N=1999)	All Abrocitinib (N=3052)
Safety Event				
Hypoglycemia	n(%) PY IR (95% CI)	2 (0.2) 2643.92 0.08 (0.01, 0.27)	6 (0.3) 4642.23 0.13 (0.05, 0.28)	8 (0.3) 7286.15 0.11 (0.05, 0.22)

Includes Studies: B7451006, B7451012, B7451013, B7451014, B7451015, B7451029, B7451036, B7451037, B7451050. Data cutoff date for B7451015: 31Dec2024
Two adult subjects who had no dosing data in the database of the previous data cut (05SEP2022) are now included after data entry.
Includes data up to the end of risk period (the smallest of [last dose date + 28 days], [death date] and [data cut date for B7451015]).
PY (Patient-Year): Total follow up time calculated up to the day of the first event for subjects with events, and up to the end of risk period for subjects without events.
n: Number of subjects with the event. Incidence Rates (IR): Number of subjects with events per 100 patient-years.
Confidence intervals (CI) were calculated for incidence rates based on the assumption that the actual count of cases arises from a Poisson distribution.
PFIZER CONFIDENTIAL Source Data: adtteae Date of ADAM Dataset Creation: 05JUN2025 Output File: ./ad_2024/LTDCP2024_289a/adae_hr_all Date of Generation: 06JUN2025 (04:20)